Market Analysis - (2020) Volume 12, Issue 3
Jason Haxton
Museum of Osteopathic Medicine and the International Center for Osteopathic History, U.S.A, E-mail: jhaxton@atsu.edu
We are happy to invite all the participants to the "World Congress on Rare Diseases and Orphan Drugs" during September 10-11, 2020 at Prague, Czech Republic, it is a special stage, we welcome scientists, masters, experts, specialists and research colleagues, educators, from everywhere throughout the world.
Orphan Drugs 2020 is a Global platform reaching across all the rare diseases around the globe, covers research and developments of new treatments. The conference attains significance when we look at the worldwide death’s due to Rare Diseases, about 30% of children with rare diseases will die before reaching their fifth birthday.
Global Orphan Drugs Market is expected to garner $169 billion from $106 billion and register a CAGR of 6.8% during the forecast period, 2016-2022. Orphan drugs can be defined as a pharmaceutical agent specifically designed to treat rare diseases.
The demand for the orphan drugs has increased significantly owing to surge in prevalence of rare diseases. In addition, rise in awareness among the populace regarding the rare diseases, increase in R&D investment, and drug development drive the market growth. The orphan drugs market is segmented based on disease type, indication, and geography. Based on disease type, the industry is divided into oncologic diseases, metabolic diseases, hematologic & immunologic diseases, infectious diseases, neurologic diseases, and other rare diseases.
The regional evaluation of the global orphan drug market includes regions such as Americans, Europe, Asia- Pacific, and Middle East & Africa. Among them, Americans were accounted for being the largest market share of 39.98% in 2017. The Americans is also probable to lead the global orphan drugs market at the time of the assessment period. Therefore, the growth of orphan drugs market in this region is mainly proliferating owing to the increasing commonness of rare disorders.
The European orphan drugs market is also expected to be at the second-largest position during the assessment period owing to the rising number of pharmaceutical companies that are incessantly exporting drugs outside or within Europe.
This is somehow expected to contribute the market growth of orphan drug in the years to come. While most of the European companies are engaged in research and development of orphan drug’s according to the patient’s need, this is expected to mount with new opportunities in coming years owing to favourable factors such as the introduction of innovative technologies, stable pricing, reimbursement, unmet medical necessities, and strong clinical pipeline.
Contact:
Jessica Roy |
Program Manager Pharmaceutical Sciences 2020
orphandrugs@europemeet.org
